Edition:
United Kingdom

Cyclacel Pharmaceuticals Inc (CYCC.OQ)

CYCC.OQ on NASDAQ Stock Exchange Capital Market

1.71USD
7:21pm GMT
Change (% chg)

$0.00 (+0.00%)
Prev Close
$1.71
Open
$1.69
Day's High
$1.73
Day's Low
$1.68
Volume
31,377
Avg. Vol
89,708
52-wk High
$10.90
52-wk Low
$1.53

Select another date:

Thu, Nov 9 2017

BRIEF-Cyclacel Pharmaceuticals Q3 loss per share $0.91 including items

* Cyclacel Pharmaceuticals reports third quarter 2017 financial results

BRIEF-Intra-Cellular Therapies Q3 loss per share $0.53

* Intra-Cellular Therapies reports third quarter 2017 financial results and provides corporate update

BRIEF-Intra-Cellular Therapies ‍announces positive topline data with Lumateperone

* Announces positive topline data from 6-week open-label safety switching study with Lumateperone in patients with schizophrenia​

BRIEF-Intra-Cellular Therapies announces positive regulatory update on schizophrenia program

* Intra-Cellular Therapies announces positive regulatory update on schizophrenia program

BRIEF-Cyclacel Pharmaceuticals Q2 loss per share $0.50

* Cyclacel Pharmaceuticals reports second quarter 2017 financial results

BRIEF-Intra-Cellular Therapies reports Q2 loss per share $0.41

* Intra-Cellular Therapies reports second quarter 2017 financial results and provides corporate update

BRIEF-Cyclacel announces selection of recommended phase 2 dose for CYC065

* Cyclacel announces selection of recommended phase 2 dose for CYC065 and evidence of durable target engagement and MCL-1 biomarker suppression Source text for Eikon: Further company coverage:

BRIEF-Cyclacel announces pricing of $13.2 mln underwritten public offering

* Cyclacel announces pricing of $13.2 million underwritten public offering

BRIEF-Cyclacel Pharmaceuticals says approved extension of employment agreements with CEO and CFO

* Cyclacel pharmaceuticals - compensation and organization development committee approved extension of employment agreements with ceo spiro rombotis, cfo paul mcbarron

Select another date: